

Supplemental Table 1. Clinical parameters at the time of liver biopsies (Case 1, 2, 3, and 4)

	Case 1 (male, 64 years at 1st biopsy)			Case 2 (male, 44 years at 1st biopsy)			Case 3 (female, 60 years at 1st biopsy)			Case 4 (female, 63 years at 1st biopsy)		
	1st biopsy* (At pretreatment)	2nd biopsy* (At 24 weeks)	3rd biopsy (At 3.8 years)	1st biopsy* (At pretreatment)	2nd biopsy* (At 24 weeks)	3rd biopsy (At 3.5 years)	1st biopsy* (At pretreatment)	2nd biopsy* (At 24 weeks)	3rd biopsy (At 3.5 years)	1st biopsy* (At pretreatment)	2nd biopsy* (At 24 weeks)	3rd biopsy (At 3.5 years)
Physical examination												
Body mass index (kg/m ²)	23.5	22.3	23.2	25.3	25.0	25.2	27.9	26.3	27.8	27.8	25.5	26.2
Waist circumference (cm)	76.6	73.6	79.2	96.9	94.4	96.2	88.1	81.2	87.2	89.2	86.3	87.0
Comorbidities												
Hypertention (Treatment)	Yes (CCB)	Yes (CCB)	No	No	No	No	No	No	No	No	No	No
Dyslipidaemia (Treatment)	Yes (HMG-CoA reductase inhibitor)	Yes (HMG-CoA reductase inhibitor)	Yes (HMG-CoA reductase inhibitor)	No	No	No	Yes (HMG-CoA reductase inhibitor)	Yes (HMG-CoA reductase inhibitor)	Yes (HMG-CoA reductase inhibitor)	Yes (No treatment)	Yes (No treatment)	Yes (HMG-CoA reductase inhibitor)

Antidiabetic agents, expect for SGLT2 inhibitor	No	No	No	Yes (Sulfonylurea)	Yes (Sulfonylurea)	Yes (Sulfonylurea)	Yes (Sulfonylurea)	Yes (Sulfonylurea)	Yes (Glinide, DPP-4 inhibitor)	No	No	No
Laboratory data												
Serum aspartate aminotransferase (U/L)	22	20	28	10	10	9	19	18	13	39	21	21
Serum alanine aminotransferase (U/L)	24	17	45	17	17	14	23	27	12	63	19	19
Alkaline phosphatase (U/L)	249	261	282	226	233	396	235	211	317	363	269	320
Gamma-glutamyl transpeptidase (U/L)	42	35	57	42	27	35	23	19	20	36	21	17
Estimate glomerular filtration rate (ml/min/1.73)	64.4	68.5	64.1	112.5	106.0	102.3	88.7	73.0	82.0	64.5	60.7	69.0

m ³)												
Fasting plasma glucose (mg/dL)	126	106	107	265	182	281	180	140	161	106	97	108
C-peptide (ng/mL)	2.30	1.86	1.82	2.10	1.76	1.94	3.47	1.53	0.99	3.84	1.70	3.89
HbA1c (%)	6.6	6.6	6.8	12.0	10.3	14.9	7.5	7.5	8.1	7.9	6.4	6.6
HOMA-IR	4.9	1.7	2.0	not done	2.9	2.4	3.2	1.3	1.3	9.4	5.0	3.5
HOMA-β (%)	65	42	47	not done	16	8	21	20	10	186	185	100
Total cholesterol (mg/dL)	168	175	195	217	212	217	188	158	172	210	217	147
Triglycerides (mg/dL)	232	103	173	153	288	198	191	136	244	105	85	99
High-density lipoprotein cholesterol (mg/dL)	40	55	53	37	44	40	45	44	55	37	38	30
Low-density lipoprotein cholesterol (mg/dL)	84	96	121	149	122	150	97	79	84	145	146	108
Uric acid (mg/dL)	6.7	5.4	5.0	4.4	5.0	4.0	5.9	5.7	5.1	5.5	5.2	4.7
Hyaluronic acid (μg/L)	16	20	36	17	5	17	42	23	36	102	80	96

Type IV collagen 7S (ng/mL)	4.4	3.0	4.2	4.4	2.3	4.9	3.8	2.9	3.6	4.9	4.2	4.1
Procollagen III peptide (U/mL)	0.54	0.60	0.60	<0.50	<0.50	<0.50	<0.50	0.70	0.60	0.70	0.70	0.60
High sensitive C-reactive protein (mg/dL)	0.081	0.150	0.072	0.026	0.026	0.020	0.062	0.084	0.123	0.075	0.063	0.064
Serum ferritin (µg/L)	233	123	208	259	183	187	202	99	50	602	298	216
Fibrosis-4 index	1.15	1.40	1.45	0.55	0.67	0.41	1.04	0.87	0.91	2.01	1.46	1.66
Imaging												
Liver stiffness measurement with transient elastography (kPa)	5.8	4.9	3.5	4.2	2.9	5.0	5.1	3.6	6.3	9.9	6.8	5.2
Liver fat with magnetic	12.1	6.7	11.8	13.6	9.7	2.8	8.9	4.2	14.0	16.5	11.5	9.7

resonance
spectroscopy
(%)

*Results of 1st and 2nd liver biopsies, are based on the previous prospective study (Reference 8,9).

CCB; Calcium channel blocker, DPP-4; dipeptidyl-peptidase 4, HMG-CoA; 3-hydroxy-3-methylglutaryl-coenzyme A.